ABSTRACT The effects of dobutamine ([±] ¶4-[2- [[3-(p-hydroxyphenyl itg/kg/min, the drug increased dP/dt/P from 65±3 to 128i4 s' and isolength velocity from 72±4 to 120+7 mm/s without affecting LV end diastolic D significantly. Mean arterial P rose from 92±2 to 104±3 mm Hg and heart rate from 78±3 to 111+7 beats/min, while LV end systolic D fell from 24.1±+1.4 to 19.9±1.8 mm, reflecting a rise in stroke volume from 30±4 to 42±3 ml. Cardiac output rose from 2.41±0.23 to 4.35±0.28 liter/min, while calculated total peripheral resistance declined from 0.042+0.005 to 0.028±0.003 mm Hg/ml/min. The greatest increases in flow and decreases in calculated resistance occurred in the iliac and coronary beds, and the least occurred in the renal bed. Propranolol blocked the inotropic and betas dilator responses while vasoconstricting effects mediated by alpha adrenergic stimulation remained in each of the beds studied. When dobutamine was infused after a combination of practolol and phentolamine, dilatation occurred in each of the beds studied. These observations indicate that dobutamine is iDr.
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INTRODUCTION
Cardioactive sympathomimetic amines are frequently administered in a variety of situations involving "myocardial pump failure," particularly in states of cardiogenic shock after acute myocardial infarction, and after cardiopulmonary bypass. However, opinions as to the efficacy of these agents differ considerably (1) . Iso- proterenol, a potent inotropic agent by virtue of its pure beta adrenergic stimulating properties, is frequently used in myocardial pump failure regardless of the etiology (2, 3); however, unfavorable effects, e.g., excessive tachycardia, arrhythmias, and reduced perfusion pressure, often occur as well (4, 5) . Furthermore, isoproterenol has been shown experimentally to extend infarct size after coronary occlusion (6) , to intensify myocardial ischemia after coronary narrowing resulting in acute cardiac failure (7) , and to impair left ventricular (LV)1 function when coronary blood flow is restricted (8) . Norepinephrine, on the other hand, while stimulating myocardial contractility, also causes a marked increase in peripheral resistance and coronary vasoconstriction as a consequence of its potent alpha adrenergic properties (9) ; these actions can also be deleterious. Dopamine is now administered frequently because it increases myocardial contractility and cardiac output (CO) with less alpha adrenergic vasoconstriction than norepinephrine and less cardiac acceleration than isoproterenol (10, 11) . Nevertheless, dopamine exerts considerable alpha adrenergic stimulation (12, 13) and this property in combination with its tendency to elicit arrhythmias may limit its usefulness (14, 15) 8, 20 , and 40 gg/kg in 13 dogs. This sequence was repeated while maintaining HR constant by electrical stimulation of the atria in seven dogs, and after beta adrenergic blockade with propranolol, 1-2 mg/kg, in nine dogs. On separate days the control protocol was repeated and dobutamine was also administered first after practolol, 4 mg/kg, and then after phentolamine, 1 mg/kg, in nine dogs. In the experiments in which coronary blood flow was measured, dobutamine was administered after practolol, 4 The effects of dobutamine on myocardial force-velocity relations were assessed by determining their effects on the V of shortening, i.e. dD/dt, and intraventricular P at an identical ventricular D (isolength point), by the technique described in detail previously (9, 13, 17, 20) . All isolength points were obtained during the first one-third of ejection. In addition, the effects on peak dP/dt and the quotient of dP/dt and developed P (LV minus end diastolic P, i.e., (dP/dt) /A, were examined. The same level of P which occurred during isovolumic contraction, before and after each intervention and ranged from 40 to 80 mmHg, was used for this calculation and dP/dt and P were determined at that level of pressure. This technique for evaluating the myocardial contractile state has also been described in detail previously (9, 13, 16, 21) . Measurements after the drug were compared to control observations and changes from control in the different states were compared with the paired t test (22) . Average (Fig. 1) (Fig. 2) . Mean AP increased mimimally with increasing dosage.
Beta-blockade. Propranolol modified the response to dobutamine in the following manner: Substantially greater (P < 0.02) increases in mean AP occurred (Fig. 2) , and the small HR increase that did occur in the unblocked state was prevented, presumably by the combination of baroreceptor reflex vagal activation and the blockade of the slight direct chronotropic effect. CO and stroke volume, instead of rising, fell at the highest dose from 2.45+0.32 to 2.15±0.26 liter/min, and from 28±3 to 23±3 ml. In the face of blockade of beta adrenergic receptors in the systemic vascular bed, the alpha adrenergic stimulating properties of the drug were unmasked and TPR rose rather than fell, as had occurred in the control, unblocked state (Fig. 2) .
Beta. and alpha blockade. The combination of practolol and phentolamine modified the response to dobutamine by preventing the betai adrenergic receptor-mediated increases in HR and contractility and the alpha adrenergic-mediated vasoconstriction, leaving beta2 adrenergic receptor-mediated vasodilatation. Dobutamine caused a small, insignificant increase in cardiac output from 2.43±0.30 to 3.10+0.48 liter/min, and a reduction in stroke volume from 26±5 to 24±6 ml. Mean AP fell from 98±4 to 78±1 mm Hg, a change which differed significantly (P < 0.01) from that which occurred in the unblocked state or after propranolol, -and which reflects the betas adrenergic receptor-stimulating properties of the drug. TPR fell from 0.043±0.006 to 0.027±0.005 mm Hg/ml/min (P <0.001).
P, D, and myocardial contractility Spontaneous rhythm. Dobutamine elicited progressive increases in myocardial contractility (Fig. 3) , as reflected by increases (with the largest dose), in peak dP/dt from a control level of 3,420±+160 to 8,200+560 mm Hg/ml/min, dP/dt/P from 65±3 to 128+4 so, isolength V from 72±4 to 120±7 mm/s, with a corresponding increase in isolength systolic LVP from 113±4 to 138±4 mm Hg (Fig. 4) . These increases in contractility were not accompanied by significant changes in LV end diastolic P or D, while end systolic D fell progressively from 24.1±1.4 to 19.9±1.8 mm (P < 0.001) (Fig. 4) (Fig. 6) ; mean coronary resistance rose from 2.26±0.23 to 2.71±0.25 mm Hg/ml/ min, demonstrating the slight but significant (P < 0.05) vasoconstricting effects mediated by stimulating alpha adrenergic receptors in the coronary bed.
Betai and alpha blockade (HR constant). Practolol prevented the beta, adrenergic receptor-mediated increases in contractility. Dobutamine then increased coronary flow only slightly, from 38±3 to 45±4 ml/min (P < 0.05) but did not affect coronary resistance significantly (Fig. 6) suggesting that the vasodilator action mediated by betas adrenergic receptors was opposed by the alpha constrictor action of the drug. With the addition of phentolamine, the beta2 properties were unmasked; coronary flow rose from 39±4 to 47±5 ml/min (P < 0.02) and coronary resistance fell from 2.34±0.22 to 1.59±0.18 mm Hg/ml/min (P <0.001) (Fig. 6) .
Distribution of blood flows and resistances The unblocked state. As mentioned above, at 8 /ug/ kg/min only the coronary bed was affected significantly. At 20 *g/kg/min, only the coronary and iliac beds manifested increases in flow and decreases in resistance (Fig. 5) . At the 40 Ag/kg/min dose, all four beds studied exhibited increased flows and decreased resistances, but the relative changes from control in the coronary and iliac beds were significantly greater (P < 0.001) than those in the mesenteric bed, while the changes in the mesenteric bed were significantly greater (P < 0.05) than those in the renal bed. At the highest dose, 0.01), while resistance in this bed declined from 0.99± 0.10 to 0.62±0.08 mm Hg/rnl/min (P<0.01); mesenteric flow rose from 467±42 to 530±49 ml/min (P < 0.01) and resistance fell from 0.23±0.017 to 0.20±0.014 mm Hg/ml/min (P < 0.05). The renal bed showed the least response: flow rose from 183±15 to 190±15 ml/ min (NS) and resistance fell from 0.57+0.037 to 0.54± 0.021 mm Hg/ml/min (NS). Beta-blockade. Propranolol unmasked the alpha adrenergic receptor properties of the drug and resulted in reduced flows and increased resistance in the mesenteric, renal, and iliac beds (Fig. 7) .
Betai and alpha blockades. Practolol and phentolamine unmasked the betas adrenergic receptor properties of the drug. Dobutamine then produced substantial dilatation in each of the regional beds. The iliac bed showed relatively greater (P < 0.01) increases in flow (139±8%) and decreases in resistance (-61±5%) tthan occurred in the renal and mesenteric bed, suggesting a greater density and/or sensitivity of betas adrenergic receptors in that bed.
Comparison of dobuitamine with other sympathomimetic amines Isoproterenol, norepinephrine, dopamine, and epinephrine were infused individually into the same dogs in concentrations which matched the increases in dP/dt (from 3,380±180 to 8,290±650 mm Hg/s) that occurred with the infusion of dobutamine (40 pg/kg/min) (Fig. 8) . This dose of dobutamine raised mean AP by 7±6 mm Hg and HR by 43±11 beats/min.
Isoproterenol resulted in a decline in mean AP by 14± 1.0 mm Hg (P = 0.05) while HR rose to a far greater extent, by 126±6 beats/min (P < 0.01) than after dobutamine.
Norepinephrine caused a much greater (P < 0.05) increase in mean AP (+ 71±11 mm Hg) but a significantly smaller increase in HR (+ 14±10 beats/min) (P <0.05). (Fig. 8) ; both of these effects can be deleterious in the presence of pump failure due to myocardial ischemia (4, 7, 8) . On the other hand, equi-inotropic doses of norepinephrine, epinephrine, and dopamine caused significantly greater pressor responses than dobutamine, suggesting that they produced more powerful alpha adrenergic stimulation. Moreover, dopamine increased HR to a greater extent than did dobutamine and in conscious dogs uniformly resulted in emesis at an inotropic level, which was consistently reached with dobutamine without evidence of adverse somatic or visceral effects. Thus, in comparison with isoproterenol, norepinephrine and dopamine, dobutamine exerts less undesirable effects on AP and HR in the normal dog. While dobutamine appears to exert its main action on myocardial betai adrenergic receptors, resulting in augmented contractility, it also has significant effects on beta2 and alpha adrenergic receptors in the vascular bed. Simulation of these beta2 adrenergic receptors, which was unmasked after the administration of the combination of practolol and phentolamine, was most intense in the coronary and iliac vascular beds, but less evident in the mesenteric and minimal in the renal bed. While, under certain circumstances, coronary beta2 adrenergic receptor-mediated vasodilatation might be beneficial, under others a redistribution of CO favoring the muscle beds at the expense of the kidney and viscera might be deleterious.
Dobutamine possesses alpha adrenergic stimulating properties as well, which to some extent, offset the beta2 adrenergic receptor vasodilating properties of the drug. The alpha adrenergic effects were shown clearly after beta adrenergic receptor blockade with propranolol. After propranolol, dobutamine's inotropic effects were abolished and vasoconstriction was observed in each of the regional beds studied. In that situation the LV as well as the peripheral vascular effects of dobutamine were radically different; stroke volume and CO fell instead of rising, end systolic D rose instead of falling, and end diastolic D rose substantially.
The response of the coronary bed to dobutamine involved a combination of actions, the sum of which was substantial vasodilatation. The difference between the responses before and after practolol represented the amount of coronary dilatation secondary to increased myocardial metabolic demand induced primarily by the powerful positive inotropic action of the drug. After practolol alone, dobutamine did not affect coronary resistance significantly, indicating that the remaining beta2-vasodilating and alpha-vasoconstricting properties counteracted each other, resulting in no change in coronary resistance. This was substantiated by the findings of significant coronary vasoconstriction after propranolol alone and significant coronary vasodilatation after a combination of practolol and phentolamine.
In conclusion, dobutamine, a new cardioactive sympathomimetic amine,3 shows considerable promise therapeutically. This agent may be useful in the presence of myocardial failure, where undesirable side effects of intense alpha vasoconstriction, hypotension, tachycardia, and other arrhythmias can be deleterious. However, extrapolation to clinical conditions such as myocardial failure or ischemia must be done cautiously, since dobutamine may well act differently in those situations than in healthy, conscious animals with normal hearts. For instance, although arrhythmias were not observed in the present study, the beta adrenergic stimulating properties of dobutamine might elicit arrhythmias in diseased hearts. The one property of this drug which does not appear to be ideal is its tendency to cause a redistribution of CO favoring the muscular beds at the expense of the kidney and visceral beds.
